Centocor gets exclusive rights to FivePrime compounds
Executive Summary
Johnson & Johnson's Centocor Research & Development has signed a deal with FivePrime Therapeutics to discover and develop pulmonary fibrosis and osteoarthritis compounds (specifically focusing on cartilage repair and regeneration).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice